Jason Smith, CTO – AI & Analytics at Within3
In Part I of this series, we explored how next-generation launch rooms are transforming pharmaceutical commercialization through real-time analytics, agile methodologies, and design thinking. In Part II, we examine the practical challenges companies face when implementing these innovations—offering a balanced look at what it takes to translate theory into impact.
The implementation gap: Why launch rooms fall short in practice
Despite their potential, pharmaceutical companies face substantial hurdles in establishing and executing next-generation launch rooms. These challenges span cultural, technological, and operational domains:
Cultural and organizational resistance
Traditional pharmaceutical organizations operate in functional silos (marketing, medical, market access) with hierarchical decision-making structures. Launch rooms fundamentally shift this paradigm by enabling a core team to make rapid, cross-functional decisions.
This shift demands significant cultural change. If stakeholders don’t trust the launch room’s data or processes, they may circumvent it, creating duplicative efforts and increasing cross-functional tension. Building trust requires transparency and support from senior leadership to empower the launch team fully. Additionally, staff must adapt to new ways of working; agile ceremonies and constant data scrutiny can be jarring for employees accustomed to longer planning cycles.
As one pharma executive shared at a recent industry conference, “The hardest part wasn’t building the room or the technology; it was convincing our organization to work differently.”
These shortcomings demonstrate that an LSR alone is not a “golden ticket” to success. However, when implemented effectively, next-generation launch rooms address these issues and elevate pharmaceutical launches to new heights of effectiveness.
Operational integration and timing
A launch room cannot be an afterthought; it needs to be integrated into launch planning well in advance. One key challenge is determining the optimal timing for establishing the launch room. Those who wait until a few months before launch often struggle with team alignment during the critical preparation period.
Best-in-class companies start a year or more ahead, despite resource implications (when the product might still be in Phase 3 trials). This extended timeline allows teams to train, define metrics, and simulate decision scenarios. Equally critical is defining clear decision rights. The team needs explicit guidance on what decisions it can make autonomously versus those that require higher approval. Without this governance clarity, the launch room may default to “reporting mode” only, undermining its purpose.
Technology and data hurdles
Next-generation launch rooms are highly data-driven, making technical infrastructure critical to success. Many companies discover that their data systems are inadequate for real-time analytics, with information siloed across disconnected market research, sales, and finance platforms.
Integrating these disparate sources into unified dashboards represents a significant IT undertaking. Teams also require robust analytics tools and the specialized talent to interpret and act on insights. As McKinsey observes, the pharmaceutical industry has been slower than other sectors to adopt AI/ML in commercial operations, with most companies still in the early stages of scaling such technologies.
Data limitations—such as restricted physician-level data outside the U.S. or quality issues—can further hinder decision-making and must be addressed to support the LSR.. Data governance and security also present concerns, especially when aggregating patient-level information across markets.
Sustaining new ways of working
Establishing a launch room is only the beginning—sustaining its agility and collaboration over time can be even more difficult. As the intense launch window passes, organizations risk reverting to “business as usual,” dispersing cross-functional teams and losing momentum.
Scaling the launch room model across multiple products or geographies presents another layer of complexity. Launch Excellence research highlights that few pharmaceutical companies manage to reliably repeat launch success across different products or markets—each launch team often “reinvents the wheel.” Some firms are creating permanent launch centers of excellence or standardized frameworks to address this issue, but this approach continues to evolve.
Additionally, agile launch rooms require quick decision cycles that may clash with slower-moving organizational processes (such as global compliance reviews or medical/legal approvals). Navigating these intersections – effectively bridging the agile launch team with broader enterprise processes – requires careful planning, such as pre-aligning on fast-track approval processes for launch content.
Pharmaceutical launch rooms in 2025: The path forward
As 2025 unfolds, several key trends are reshaping how pharmaceutical companies plan and execute product launches. From AI-driven insights to more connected ecosystems, next-generation launch rooms are at the center of this transformation.
Digital acceleration and AI integration
Pharmaceutical companies are rapidly advancing their digital transformation efforts, with 89% of industry leaders now implementing or developing digital strategies (up 10% from 2022). AI applications could create between $350 billion and $410 billion in annual value for pharmaceutical companies by 2025, according to recent industry analyses.
Launch rooms are increasingly incorporating AI capabilities to optimize targeting, analyze patient journeys, and predict market responses. As one executive at the 2024 Pharma Launch Excellence Summit observed, “The emphasis on agility, collaboration, and innovation stood out. These often-overlooked capabilities can determine the success or failure of a launch.”
Pharma 4.0™ and connected launch ecosystems
The industry’s shift toward Pharma 4.0™—a framework for digital integration across the pharmaceutical value chain—is enabling more seamless coordination between clinical development, supply chain, commercial operations, and market access.
Launch rooms are evolving to become nerve centers within these connected ecosystems, enabling more seamless information flow and coordination. The 2024 ISPE Pharma 4.0™ Conference highlighted how digitalization has “opened new avenues for reducing end-to-end timelines, enabling faster and more efficient batch release processes.”
Cross-functional agility beyond software development
Agile practices—once confined to software development—are gaining traction across pharmaceutical functions. As one industry source notes: “There’s been a realization that the rigid, sequential processes that worked in the past are insufficient for today’s market dynamics.”
Implementing agile practices in pharmaceutical environments presents unique challenges, particularly given regulatory requirements. However, organizations are finding ways to balance compliance with flexibility. For example, the ISPE GAMP Good Practice Guide notes that in cases where the scope is less clearly defined, “Agile is a more suitable approach” that “enables faster initial system deployment and subsequent incremental development” while adhering to GxP requirements.
Balanced pragmatism for launch success
While next-generation launch rooms offer significant strategic value, their success hinges on thoughtful execution. Organizations that benefit most are those approaching implementation with clear-eyed pragmatism—balancing innovation with operational reality.
The most effective pharmaceutical companies are focusing on five critical areas:
- Start early and secure executive sponsorship. Launch room planning should begin at least 12 months before launch, backed by visible C-suite support.
- Build the right data and analytics foundation.: Invest in the infrastructure needed to deliver real-time insights—before the launch room goes live.
- Define clear decision rights and governance models: Explicitly outline what decisions the launch team can make independently to avoid ambiguity and delays.
- Cultivate a culture receptive to agile collaboration: Address resistance proactively through training and change management to build buy-in and alignment.
- Scale with intention: Use centers of excellence to standardize successful practices and create repeatable launch capabilities.
As the pharmaceutical industry faces compressed exclusivity windows, demanding payers, and intensifying competition, the agile launch room approach is likely to gain further adoption. But as McKinsey notes, a launch room is not a “golden ticket” – its ultimate value depends on execution quality and alignment with the organization’s broader capabilities and culture.
The companies that succeed won’t treat launch rooms as one-off initiatives, but as catalysts for broader operational transformation, driving excellence under high-pressure conditions while building capabilities that last beyond any single product launch.
Learn how Within3 can help you build these lasting capabilities. Request a demo today.
